Clinical Trial: Phase 1 Study of SL-325 in Healthy Volunteers

U.S., Sept. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07158437) titled 'Phase 1 Study of SL-325 in Healthy Volunteers' on Aug. 28.

Brief Summary: This first-in-human study is a randomized, double-blind, placebo-controlled, single-ascending dose and multiple-ascending dose study of SL-325 in healthy volunteers.

Study Start Date: Sept., 2025

Study Type: INTERVENTIONAL

Condition: Healthy Volunteers

Intervention: BIOLOGICAL: SL-325

DR3 blocking antibody

OTHER: Placebo (Normal Saline)

Normal saline

Recruitment Status: RECRUITING

Sponsor: Shattuck Labs, Inc.

Disclaimer: Curated by HT Syndication....